An Ultra-Thin Polymer Coating for the Tethering of Adenoviral Vector to the Surface of Coronary Stents by Fishbein, Ilia et al.
University of Pennsylvania
ScholarlyCommons
Departmental Papers (CBE) Department of Chemical & BiomolecularEngineering
5-2003
An Ultra-Thin Polymer Coating for the Tethering
of Adenoviral Vector to the Surface of Coronary
Stents
Ilia Fishbein
The Children's Hospital of Philadelphia
Ivan S. Alferiev




University of Pennsylvania, vohs@seas.upenn.edu
Jeanne M. Connolly
The Children's Hospital of Philadelphia
See next page for additional authors
Follow this and additional works at: http://repository.upenn.edu/cbe_papers
Part of the Biochemical and Biomolecular Engineering Commons, Materials Science and
Engineering Commons, and the Polymer Science Commons
This paper is posted at ScholarlyCommons. http://repository.upenn.edu/cbe_papers/173
For more information, please contact repository@pobox.upenn.edu.
Recommended Citation
Fishbein, I., Alferiev, I. S., Wong, G., Vohs, J. M., Connolly, J. M., Wilensky, R. L., & Levy, R. J. (2003). An Ultra-Thin Polymer Coating
for the Tethering of Adenoviral Vector to the Surface of Coronary Stents. Molecular Therapy, 7 (5, Supplement), S329-S330.
http://dx.doi.org/10.1016/S1525-0016(16)41295-5
An Ultra-Thin Polymer Coating for the Tethering of Adenoviral Vector to
the Surface of Coronary Stents
Abstract
Our group has previously demonstrated stent-based gene delivery with either viral or plasmid vectors.
However, these previous studies utilized bulky PLGA or collagen stent coatings, known to cause inflammatory
reactions in stented arteries. In the present experiments we successfully attached adenoviruses either directly,
or via anti-adenovirus antibodies to the steel surface of stents using chemical coordination with
biphosphonates.
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851. Suppression of Chemical Burn-Induced
Neovascularization by Subconjunctival Injection
of Adeno-Associated Virus Vector Expressing
Angiostatin
Lai Li-Ju,1,2 Li Juan,2 Tsao Yeou-Ping,1 Xiao Xiao.2
1Department of Ophthalmology, Chang Gang Memorial Hospital,
Taipei, Taiwan; 2Department of Molecular Genetics and
Biochemistry, University of Pittsburgh, Pittsburgh, PA, United
States.
Ocular neovascularization (NV) is one of the leading courses of
blindness. Many ocular surface diseases such as dry eye syndrome,
ocular cicatritial phemphigoid (OCP), limbal insufficiency and sequel
of chemical burn frequently lead to cornea NV. The underling
mechanisms of these diseases include chronic inflammation,
autoimmune response and stem cell loss. This major ocular
complication can led to corneal scarring, edema, lipid deposition,
and inflammation that may not only significantly alter visual acuity,
but also worsen the prognosis of the subsequent penetrating
keratoplasty (PKP). Since ocular surface diseases usually have
protracted courses, the control of their respective detrimental
mechanisms usually depend on long term application of steroid or
cytotoxic or immunosuppressive medications such as
cyclophosphamide and cyclosporine A. Local and systemic side
effects create dilemma for clinician. On the other hand, the
recombinant AAV vector is currently considered as one of the most
promising viral vectors for gene therapy. In this study, we investigate
the efficacy of AAV vectors in a rat model of experimental corneal
NV generated by silver nitrate (AgNO3) cauterization. The vectors
contained either the mouse angiostatin gene (AAV-angiostatin) or
the control green fluorescent protein gene (AAV-GFP). Two weeks
after subconjunctival injection the vectors, gene transfer efficiency
and therapeutic efficacy were evaluated under slit-lamp
biomicroscopy every other day. Vessel length was measured by
fluorescent isothiocyanate (FITC)-coupled concanavalin A (ConA)
lectin angiography. AAV-angiostatin successfully suppresses the
chemical-burn induced corneal NV as shown by Angiography
analysis. The areas free from blood vessel invasion in the cornea
correlated with the sites of virus injection. The therapeutic effect
lasted for the entire 12-week duration of our experiments, while
AAV-GFP expression persisted more than 6 months. This is the
first report that subconjunctival injection of AAV-angiostatin can
significantly inhibit the formation of corneal NV lesion. Importantly,
subconjunctival injection can be used as a unique reversible gene
therapy method. Therefore, the AAV vector represents a promising
gene delivery system for efficient and long-term transduction in
ocular tissue. Our study demonstrated the feasibility of gene therapy
approaches for the treatment of corneal NV diseases. It may also
become clinically useful for a variety of ocular diseases involving
NV, such as wound- and inflammation-related corneal angiogenesis
with limbal insufficiency, which is still pharmacologically untreatable.
852. Development of a Retroviral Vector
Containing the Erythroid Band 3 Promoter
Flanked by the Chicken β-Globin 5’HS4 Insulator
Robert I. Liem,1 Tiffany F. Frazar,1 Nancy E. Seidel,1 Lisa J.
Garrett,2 Patrick G. Gallagher,3 David M. Bodine.1
1Genetics and Molecular Biology Branch, National Human
Genome Research Institute, Bethesda, MD, United States;
2Genetic Disease Research Branch, National Human Genome
Research Institute, Bethesda, MD, United States; 3Department of
Pediatrics, Yale University School of Medicine, New Haven, CT,
United States.
Expression of genes in retroviral vectors is subject to the epigenetic
effects of surrounding heterochromatin after integration, resulting in
transgene silencing or position effect variegation (PEV).  It has been
shown that an insulator element from the chicken β-globin locus
(5’HS4) serves as a barrier against such position effects and thereby
promotes long-term, uniform expression of a transgene but the
mechanism by which an insulator suppresses PEV has not been
elucidated. The erythroid anion exchanger 1 (AE1 or band 3)
promoter is active only in erythroid cells.  Using a transgenic mouse
assay, we have analyzed human γ-globin gene expression using
promoter elements from the erythroid form of the AE1 gene.
Transgenic mice containing 2 different AE1 promoter sequences, -
1738 to +22 (9 lines) or -357 to +22 (9 lines), fused to the γ-globin
gene coding region 5 bases upstream of the initiation codon showed
erythroid specific expression of the transgene with an average AE1/
γ-globin mRNA level of 13.5±0.07% and 7.3±0.04% of total mouse
α-globin mRNA per transgene copy, respectively.  With both
promoters, γ-globin expression was position independent and copy
number dependent.  However, γ-globin distribution in circulating
erythrocytes was variegated in 14/18 lines.  We hypothesized that
flanking the 5’ and 3’ ends of the -1738 to +22 AE1/γ-globin gene
construct with the chicken 5’HS4 would suppress PEV, resulting in
more uniform expression of the transgene.  In transgenic mice
containing the insulated, long AE1/γ-globin construct, expression of
the transgene was erythrocyte specific, position independent (6/6
lines express) and copy number dependent (p = 0.0001).  Transgenic
mice had an average AE1/γ-globin mRNA level of 19.8±0.03% of
total mouse α-globin mRNA per transgene copy.  AE1/γ-globin
mRNA from the non-insulated construct initiated at cryptic sites
upstream of the start site used by the endogenous gene.  In contrast,
the insulated AE1/γ-globin construct initiated transcription at the
start site used by the endogenous gene.  Distribution of γ-globin in
all 6 lines was also uniform, with 100% of erythrocytes containing
human γ-globin.  We conclude that the erythroid AE1 promoter
contains an insulator element upstream of position -1738.
Furthermore, the chicken 5’HS4 insulator suppresses PEV by
directing transcription initiation to the correct start site.  We have
constructed an oncoretroviral vector containing the -357 to +22
AE1/γ-globin gene with the chicken 5’HS4 insulator in the 3’LTR.
Stable transduction of the AE1/γ-globin gene and transfer of 5’HS4
to the 5’LTR was demonstrated by Southern blot analysis of
transduced K562 cell DNA.  We hypothesize that an insulated




853. An Ultra-Thin Polymer Coating for the
Tethering of Adenoviral Vector to the Surface of
Coronary Stents
Ilia Fishbein,1 Ivan S. Alferiev,1 Gordon S. Wong,2 John M. Vohs,2
Jeanne M. Connolly,1 Robert L. Wilensky,3 Robert J. Levy.1
1Cardiology, The Children’s Hospital of Philadelphia,
Philadelphia, PA; 2Chemical Engineering, University of
Pennsylvania, Philadelphia, PA; 3Cardiology, University of
Pennsylvania Hospital, Philadelphia, PA.
Our group has previously demonstrated stent-based gene delivery
with either viral or plasmid vectors. However, these previous studies
utilized bulky PLGA or collagen stent coatings, known to cause
inflammatory reactions in stented arteries. In the present experiments
we successfully attached adenoviruses either directly, or via anti-
adenovirus antibodies to the steel surface of stents using chemical
coordination with bisphosphonates. Bisphosphonate derivatives
of polyallylamine possessing primary amines (PAA-BP), or both
primary amines and latent thiols (PrSSPAA-BP) were custom
synthesized. The dynamics of PrSSPAA-BP adsorption to the






surface of 316L stainless steel was studied using a compound
comprised of a fluorescent marker, dansyl, attached to the polymer
backbone through a cleavable bond. Fluorometric studies showed
fast (less than 1 hour) saturation of the steel surface with PrSSPAA-
BP. Estimation of the bound polymer amount (10-12 M/cm²)
corresponds to monolayer deposition of the polymer. Additionally,
XPS analysis confirmed the presence of the polymer and showed
that the thickness of polymer coating does not exceed 5 nm. Reaction
between primary amines in the polymer coating and the bifunctional
cross-linker, SPDP, was employed to introduce thiol-reactive,
pyridyldithio (PDT) groups on the stent surface. A panel of reduced
anti-adenoviral antibodies (anti-hexon, anti-fiber and anti-knob) was
used for the virus-tethering purposes. Monoclonal anti-knob
antibody (AkAb) was found to be the most effective in terms of the
amount of tethered AdV (108-109/cm²). The attachment of AdV to
AkAb-primed surface was profoundly inhibited (87%) by a 1000-
fold excess of knob protein. Alternatively, vector immobilization
was achieved by SPDP modification of AdV with subsequent
covalent tethering to deprotected thiols in the PrSSPAA-BP coating.
Disulfide bridges emerging during the latter immobilization scheme
may be cleaved by endogenous reducing compounds, regenerating
viable AdV particles. However, the direct tethering procedure is far
less effective than Ab-mediated immobilization both in terms of
bound vector amount, and overall transduction success. Stainless
steel meshes with tethered AdV-GFP placed in confluent cultures
of A10 cells have driven 90% transduction of cells within 50 μm of
the mesh borders, while the same amount of free virus (MOI=1)
does not result in measurable cell transduction. Moreover, meshes
recovered from the A10 culture and transferred to new cultures
retained their transducing potential up to a fourth round of relocation.
Stents bearing AkAb-tethered AdV-GFP were deployed in rat carotid
arteries (n=8). The extent of transgene expression in the stented
arteries was determined by immunohistochemistry 1, 3 and 7 days
after deployment. GFP-positive cells were abundant in arterial media
and adventitia at 7 days. In conclusion, we studied new strategies
for AdV immobilization on the stent surface, which allow site-
specific tethering of a clinically significant amount of the recombinant
AdV. In vitro and in vivo studies demonstrated high transduction
efficacy and superb localization of the reporter transgene expression.
854. A Novel Adenovirus Vector Producing
Multiple Isoforms of VEGF Reverses Hind Limb
Ischemia in the Mouse at Lower Doses Than
Equivalent Vectors Expressing Only a Single
VEGF Isoform
Paul R. Whitlock,1 Neil R. Hackett,1 Philip L. Leopold,1 Todd K.
Rosengart,2 Ronald G. Crystal.1
1Weill Medical College of Cornell University, New York, NY;
2Evanston Northwestern Healthcare, Evanston, IL.
Alternate splicing is a process that permits the expression of
multiple protein isoforms with overlapping biological properties
from a single gene. As an example of an alternately spliced gene we
have used human vascular endothelial growth factor (VEGF) whose
pre-mRNA is spliced to give seven isoforms of which three,
VEGF121, VEGF165 and VEGF189, represent >99% of the VEGF
expressed. Physiological angiogenesis occurs in the context of multiple
isoforms determined by alternate splicing, resulting in VEGF proteins
with overlapping properties. By contrast, as presently predicted
therapeutic angiogenesis uses only one of these isoforms. The
hypothesis of this work is that angiogenic gene therapy with the
genomic form of VEGF expressing the three major isoforms, could
be more potent than a vector expressing a single isoform. An
adenovirus vector (AdVEGF-All) expressing a cDNA/genomic
hybrid gene capable of expressing multiple human VEGF isoforms
was constructed and shown to express VEGF121, VEGF165 and
VEGF189 in a 2:2:1 ratio. The AdVEGF-All vector was given by
intramuscular injection in a model of mouse hind limb ischemia,
involving excision of a 0.6 cm portion of the iliac artery. Assessment
of blood flow recovery was then monitored up to 21 days using a
laser Doppler scanner. At 3 wk, tissues were harvested and stained
for vonWillebrand factor. Initial post-operative scans showed blood
flow in the ischemic limb to be 9 ± 1% of that in the non ischemic
limb. At a dose of 108 particle units, flow recovered to 92 ± 9% in
AdVEGF-All treated animals by day 21, compared with recovery
to 95 ±8% in AdVEGF121 treated animals and 50 ± 4% in AdNull
controls (p>0.5 comparing AdVEGF-All to AdVEGF121; p < 0.05
comparing AdVEGF-All and AdVEGF121 to AdNull). For groups
treated with 108 particle units the ratio of vessel numbers assessed
by histology were 1.42 ± 0.21 for VEGF-All, 1.39 ±0.22 for
VEGF121, and 0.67 ±0.17 for AdNull. Strikingly, however, at a
dose of 105 particle units, the recovery was 79 ± 8% in AdVEGF-
All treated animals by day 21, compared to only 56 ± 3% in
AdVEGF121 treated animals and 47 ± 3% in AdNull controls
(p<0.05 comparing AdVEGF-All to AdVEGF121 and AdNull).
Interestingly, a mixture of vectors coding individually for VEGF
121, 165, and 189 made up to a total dose of 105 particle units in a
ratio of 2:2:1, mediated recovery to 87 ±7% (p>0.5 comparing
AdVEGF-All to mixture). Histological analysis showed that the
ratio of vessel numbers in the ischemic compared to the control limb
in animals treated at a dose of 105 particle units was 0.61 ± 0.01 for
AdNull, 0.63 ±0.21 for AdVEGF121, and 1.43 ± 0.39 for AdVEGF-
All. We conclude that a mixture of VEGF isoforms provides a more
potent angiogenic response than a single isoform, suggesting that
the individual isoforms function synergistically, an observation with
important implications for gene and recombinant protein therapy.
Dr. Crystal has equity in, is a consultant to, and receives sponsored
research funds from, GenVec, Inc., Gaithersburg, Maryland, a
publicly-traded biotechnology company.
855. A Genetically Engineered Plasmid
Encoding a Zinc Finger VEGF-Activating
Transcription Factor Induces Angiogenesis in the
Rabbits with Hind-Limb Ischemia
Qunsheng Dai,1 Jianhua Huang,1 Bruce Klitzman,2 Joe Rokovich,3
Ed Rebar,4 Brian Johnstone,4 Christopher Kontos,1 Brian Annex.1
1Department of Medicine, Division of Cardiology, Duke
University and Durham Veterans Affairs Medical Center,
Durham, NC, United States; 2Division of Plastic-Surgery, Duke
University Medical Center, Durham, NC, United States; 3Edwards
Lifesciences LLC, Irvine, CA, United States; 4Sangamo
BioSciences, Inc., Richmond, CA, United States.
BACKGROUND: Peripheral arterial disease (PAD) afflicts
hundreds of thousands of patients and is major cause of morbidity
and mortality. Therapeutic angiogenesis seeks to treat PAD via the
growth and proliferation of new blood vessels. Unfortunately this
approach has met little success when single agents have been
employed. The purpose of this study was to investigate the role of
intra-muscular injection of plasmid-DNA encoding zinc finger-based
vascular endothelial growth factor (VEGF)-activating transcription
factors (ZFP-VEGF) that will enhance multiple VEGF isoforms in
TA muscle following surgically induced hind-limb ischemia.
METHODS: In total, 23 New Zealand White rabbits underwent
femoral artery ligation and excision and were divided into two groups
at 10 days post-operatively. One group received a single unilateral
(ischemic limb TA muscle) intra-muscular injection of ZFP-VEGF
(500mg) (n=13) and the other (control) group (n=10), included b-
galactosidase injection (500mg) (n=7) and sham treatment (n=3).
The ischemic and contra-lateral TA muscles of all animals were
harvested 21 days post-operatively. In a subgroup of these rabbits,
blood flow in ischemic and non-ischemic limbs (contra-lateral limb)
